Form 4: Casdin Partners Reports Significant Share Transactions in Standard BioTools Inc.

Casdin Partners and related entities report acquiring and disposing of shares in Standard BioTools, along with grants of Restricted Stock Units (RSUs) to Eli Casdin.

Summary

• On February 28, 2025, Casdin Partners Master Fund, L.P. acquired 4,820,959 shares of Standard BioTools Inc. common stock at $1.065 per share.
• A cross-trade occurred where Casdin Amplify Fund, LP transferred 545,000 shares of common stock to the Master Fund at $1.065 per share.
• Casdin Amplify Fund, LP disposed of 545,000 shares of common stock.
• Eli Casdin received 58,215 Restricted Stock Units (RSUs) in lieu of $62,000 in cash compensation for board service.
• The RSUs vest quarterly in 2025.
• Following these transactions, Casdin Partners Master Fund, L.P. beneficially owns 59,391,780 shares indirectly.
• Eli Casdin directly owns 2,806,470 shares, including RSUs.
• Casdin Private Growth Equity Fund II, L.P. owns 13,939,637 shares indirectly.
• Casdin Private Growth Equity Fund, L.P. owns 2,744,219 shares indirectly.

Sentiment

Score: 6

Explanation: The document primarily reports transactions, with no explicit positive or negative sentiment. The RSU grant is a slightly positive signal, while the cross-trade is neutral.

Positives

• Eli Casdin's receipt of RSUs in lieu of cash compensation demonstrates commitment to the company's long-term success.
• The acquisition of shares by Casdin Partners Master Fund, L.P. could be seen as a positive sign of confidence in the company.

Negatives

• The disposal of shares by Casdin Amplify Fund, LP could be interpreted negatively, although it was part of a cross-trade.

Risks

• The vesting of RSUs is contingent upon Eli Casdin's continued service, posing a risk if he were to leave the company.
• Market fluctuations could impact the value of the shares held by Casdin Partners and related entities.

Future Outlook

The document does not contain specific forward-looking statements, but the continued vesting of RSUs throughout 2025 suggests an ongoing relationship between Eli Casdin and Standard BioTools.

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a regulatory requirement for insiders of publicly traded companies in the United States, ensuring compliance with SEC regulations.
• The reported transactions are typical for investment firms like Casdin Partners, which frequently adjust their holdings in portfolio companies.
• The use of RSUs as compensation is a common practice for aligning the interests of board members with those of shareholders.

Related Party Transactions

• The cross-trade between Casdin Amplify Fund, LP and Casdin Partners Master Fund, L.P. is a related party transaction.

Stakeholder Impact

• The transactions could influence investor perception of Standard BioTools.
• The RSU grant aligns Eli Casdin's interests with those of shareholders.

Next Steps

• Continued monitoring of Casdin Partners' holdings in Standard BioTools.
• Tracking the vesting of Eli Casdin's RSUs throughout 2025.

Key Dates